Psoriasis and The New Biologics

Psoriasis is a protracted inflammatory skin syndrome that affects more than 125 million people globally (World Health Organisation 2016). WHO (2016) noted that the condition is linkable to both multi-morbidity and mortality of people. The inception of surplus biologic drugs has changed the outcome of patients.

The development in this field has made skin clearance possible to realize as a treatment goal, as demonstrated by Mahil and Smith (2019). Psoriasis biologic drugs have been acknowledged to target tumor necrosis factor α (etanercept, adalimumab, infliximab, and certolizumab), the p40 subunit of interleukin (IL)-12 and IL-23 (ustekinumab), IL-17 (secukinumab [IL-17A], ixekizumab [IL-17A], and brodalumab [IL-17RA]), and the p19 subunit of IL-23 (IL-23p19; guselkumab, tildrakizumab, and risankizumab) (NICE 2012; Menter et al. 2019).

Biologics are medicines from constituents that you find in living things. According to the National Psoriasis Foundation (2020), biologics are not similar to the customary systematic medicines known to impact the whole immune system. These drugs ultimately target a particular part of the immune system, which makes them more effective than the traditional medicines in treating psoriasis.


Before the inception of biologics, systematic treatments such as cyclosporine, methotrexate, mycophenolate mofetil, and acitretin were utilized in treating psoriasis. Nevertheless, these prescriptions suppressed the entire immune system, which forced clinicians to perform a repetitive laboratory evaluation owing to increased renal and liver toxicity, myelosuppression, and haematologic conditions (The Dermatologist 2014). Biologics have transformed the management as well as treatment of psoriasis by supporting clinicians to directly target the significant factors in the pathogenesis of this condition (Levy et al. 2012). The growing use of biologic prescriptions, especially Adalimumab reflects the high efficiency, improved quality of life (QoL), and moderately good wellbeing profiles on patients.

Significance of the Study on Psoriasis and Biologics

Given that no one study can address such a complex and serious healthcare problem, the present study will contribute to the understanding of the dynamics facilitating the use of psoriasis biologics. Accordingly, it will offer the knowledge needed to advance the understanding of psoriasis biologics’ efficiency to improve the QoL. Finally, the exploration will contribute to the existing literature that has assessed the growing use of biologic medication to treat psoriasis.

Aim: To investigate the efficacy of biologics in treating psoriasis

i.                    To evaluate the safety of biologics in treating and managing psoriasis
ii.                  To determine the factors enhancing the use of biologics in the modern healthcare system and sector
iii.                To add to the existing literature that has assessed the use of biologics to treat psoriasis

Research questions (RQs)
i.                    Are biologics safer than traditional systematic medications?
ii.                  Are biologics effective in treating psoriasis?


Additional Files

order now with paypal
Powered by WordPress